SCHEMBL1543422

SCHEMBL1543422

CNc1ccc2cc(-c3cnc(Cl)c(NS(=O)(=O)c4ccc(OC)cc4)c3)ccc2n1

nearest known ligand 0.61

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MTOR P42345 5/20 0.61
AKT1 P31749 2/20 0.61
PIK3CA P42336 11/20 0.56
PIK3CD O00329 7/20 0.55
PIK3CG P48736 1/20 0.53
PIK3R1 P27986 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1543483 0.91 AKT1 (0.72) MTORAKT1PIK3CAPIK3CDPIK3CG
SCHEMBL1543457 0.89 MTOR (0.61) MTORAKT1PIK3CAPIK3CDPIK3CG
SCHEMBL1543840 0.85 PIK3CA (0.77) MTORAKT1PIK3CAPIK3CDPIK3CG
SCHEMBL3659890 0.82 PIK3CD (0.67) MTORPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL3756832 0.79 PIK3CD (0.77) MTORPIK3CAPIK3CDPIK3CGPIK3R1
SCHEMBL1543441 0.79 PIK3CA (0.69) MTORAKT1PIK3CAPIK3CD
SCHEMBL1621502 0.78 AKT1 (0.72) MTORAKT1PIK3CAPIK3CDPIK3CG
SCHEMBL1543375 0.77 PIK3CA (0.74) MTORPIK3CAPIK3CDPIK3CG
SCHEMBL1543553 0.77 PIK3CA (0.80) MTORAKT1PIK3CAPIK3CDPIK3CG
SCHEMBL1545100 0.77 PIK3CD (0.62) MTORAKT1PIK3CAPIK3CDPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US claimed
EP-2307400-A2 INHIBITORS OF PI3 KINASE Amgen, Inc (US) 2011-04-13 EP claimed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO claimed
EP-2307400-B1 INHIBITORS OF PI3 KINASE AMGEN INC (US) 2014-04-23 EP disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-8415376-B2 Inhibitors of PI3 kinase AMGEN INC. (US) 2013-04-09 US disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed
US-20110092504-A1 INHIBITORS OF PI3 KINASE AMGEN INC. 2011-04-21 US disclosed
EP-2307400-A2 INHIBITORS OF PI3 KINASE Amgen, Inc (US) 2011-04-13 EP disclosed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO disclosed
WO-2009155121-A2 INHIBITORS OF PI3 KINASE AMGEN INC. (US) 2009-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110092504-A1 INHIBITORS OF PI3 KINASE PIK3CA, PIK3R1, PIK3R5 MTOR 34/4885AKT1 12/4885PIK3CA 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.